PharmaEssentia Corp (藥華醫藥) yesterday said that it has applied for marketing approval for its ropeginterferon alfa-2b drug with the China National Medical Products Administration.
The company seeks approval to use the treatment for a rare type of blood cancer, polycythemia vera, it said in a regulatory filing.
The interferon drug, sold in the US under the name Besremi, is the only approved first-line treatment for polycythemia vera, with its sole competitor being the US-based Incyte Corp’s Jakafi, which has been approved as second-line treatment.
Photo: Reuters
The drug has gained approval to be used in the treatment of adult polycythemia vera patients in Taiwan, Switzerland, Israel, South Korea, the US and the EU.
The company in October said that it was targeting China and Japan as the drug’s next markets.
PharmaEssentia did not specify the estimated date of completion for the marketing application, saying in the filing that it is subject to the Chinese agency’s procedures for case acceptance.
There are about 400,000 polycythemia vera patients in China, the company added.
Polycythemia vera is a chronic, progressive myeloproliferative neoplasm, and it is primarily characterized by a high count of red blood cells, PharmaEssentia said.
The blood disorder could result in cardiovascular complications, such as thrombosis and embolism, and often develops into secondary myelofibrosis or leukemia, it said.
Besremi is PharmaEssentia’s most significant product, helping boost its revenue 383.44 percent year-on-year to NT$2.63 billion (US$85.65 million) in the first 11 months of last year, company data showed.
The company reported a net loss of NT$1.22 billion in the first three quarters of last year, due to higher marketing, management, and research and development costs.
That translated into losses per share of NT$4.37, company data showed.
Analysts said the new drug would lead to robust sales growth and operating leverage in the long term.
The company is also conducting a phase 3 clinical trial for the drug to treat essential thrombocythemia, a rare disorder in which the bone marrow produces too many platelets.
PharmaEssentia yesterday in a separate filing said that it has received positive opinions from the Data and Safety Monitoring Board for the trial.
The board comprises independent experts who review clinical study data for new drugs.
It confirmed the safety of the trial and recommended that the firm continue conducting it according to protocols, PharmaEssentia said.
Essential thrombocythemia is a myeloproliferative neoplasm characterized by an overproduction of platelets in the blood resulting from a genetic mutation.
The number of people with essential thrombocythemia is similar to those with polycythemia vera, the company said.
PharmaEssentia has registered 90 percent enrollment for the trial and plans to complete it as soon as possible, it added.
The company’s shares rose 62.8 percent last year, closing at NT$477 on Friday in Taipei trading.
The stock last month joined MSCI Global Standard Indices after it made considerable gains last year, global index provider MSCI Inc has said.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
Nvidia Corp CEO Jensen Huang (黃仁勳) today announced that his company has selected "Beitou Shilin" in Taipei for its new Taiwan office, called Nvidia Constellation, putting an end to months of speculation. Industry sources have said that the tech giant has been eyeing the Beitou Shilin Science Park as the site of its new overseas headquarters, and speculated that the new headquarters would be built on two plots of land designated as "T17" and "T18," which span 3.89 hectares in the park. "I think it's time for us to reveal one of the largest products we've ever built," Huang said near the
China yesterday announced anti-dumping duties as high as 74.9 percent on imports of polyoxymethylene (POM) copolymers, a type of engineering plastic, from Taiwan, the US, the EU and Japan. The Chinese Ministry of Commerce’s findings conclude a probe launched in May last year, shortly after the US sharply increased tariffs on Chinese electric vehicles, computer chips and other imports. POM copolymers can partially replace metals such as copper and zinc, and have various applications, including in auto parts, electronics and medical equipment, the Chinese ministry has said. In January, it said initial investigations had determined that dumping was taking place, and implemented preliminary
Intel Corp yesterday reinforced its determination to strengthen its partnerships with Taiwan’s ecosystem partners including original-electronic-manufacturing (OEM) companies such as Hon Hai Precision Industry Co (鴻海精密) and chipmaker United Microelectronics Corp (UMC, 聯電). “Tonight marks a new beginning. We renew our new partnership with Taiwan ecosystem,” Intel new chief executive officer Tan Lip-bu (陳立武) said at a dinner with representatives from the company’s local partners, celebrating the 40th anniversary of the US chip giant’s presence in Taiwan. Tan took the reins at Intel six weeks ago aiming to reform the chipmaker and revive its past glory. This is the first time Tan
RSS